Acquisition of an exclusive worldwide license for TMS-010 (a drug candidate for spinal cord injury treatment)
First written in FY2025-Q1. 3 of 5 entries say "Advanced", first in FY2025-H1. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1AdvancedAnnual report
「During the interim accounting period, the Company advanced pharmacology and efficacy studies intended for clinical application and continued preparing the clinical trial plan.」
The Company advanced pharmacology and efficacy studies for clinical application and continued clinical trial planning while maintaining exclusive worldwide development, manufacturing and commercialization rights. - FY2026-H1AdvancedAnnual report
「During the interim accounting period, the Company continued examining the necessary nonclinical studies and GMP-level formulation manufacturing and proceeded with selecting a drug-substance supplier. It also continued preparing the clinical trial plan.」
For TMS-010, the Company continued nonclinical and GMP formulation work, advanced to selecting a drug-substance supplier and continued preparing the clinical trial plan. - FY2025RestatedAnnual report
「During the fiscal year, the Company advanced the necessary nonclinical studies and examination of GMP-level formulation manufacturing required to begin clinical trials, and prepared the clinical trial plan.」
The Company maintained exclusive worldwide development, manufacturing and commercialization rights for TMS-010 and advanced nonclinical studies, GMP formulation work and clinical trial planning. - FY2025-H1AdvancedAnnual report
「For the seed targeting spinal cord injury that had been evaluated under an option agreement with Hokkaido University since July 2022, the Company entered into a license agreement with the university on 3 July of the current year and added it to its pipeline as TMS-010. Under the license agreement, the Company obtained exclusive worldwide development and commercialization rights.」
After obtaining an exclusive worldwide license for TMS-010, the Company began nonclinical studies, GMP formulation development and preparation of the clinical trial plan toward clinical entry. - FY2025-Q1First statedAnnual report
「On 3 July 2024, the Company entered into an exclusive worldwide license agreement with Hokkaido University for intellectual property relating to a spinal cord injury drug candidate held by the university. Spinal cord injury is a serious disease affecting approximately 5,000 people annually in Japan and 180,000 worldwide, for which no effective drug currently exists. Under the agreement, the Company obtained exclusive rights to develop, manufacture, use and sell the drug in all countries worldwide, including Japan.」
The Company entered into a license agreement with Hokkaido University on 3 July 2024 and acquired an exclusive worldwide license for TMS-010. The disease affects approximately 5,000 people annually in Japan and 180,000 worldwide and has no effective drug. Total payments under the agreement may be capped at approximately 30% of projected R&D expenses for the fiscal year ending February 2025.